Introducing the GO44900 clinical study for DLBCL
The future of DLBCL treatment starts with clinical research
We’re looking for around 50 people to join the GO44900 study – a clinical study that will evaluate the safety and effectiveness of an investigational drug (in combination with two approved chemotherapy drugs) in people with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
The goal of this study is to help develop treatment options for people with DLBCL in the future.
It’s important to note that the investigational drug in this study has already been approved as a treatment for people with R/R DLBCL who have received two or more prior treatments. However, the combination of the investigational drug with the two other approved drugs (gemcitabine and oxaliplatin) is investigational.
This website will provide you with more information about clinical research in general, explain why this study is being conducted, and describe what taking part would involve. The GO44900 study is registered in clinicaltrials.gov. Disclaimer: the information provided in this website is intended for a US audience only.